Cdk4/6 inhibitors in breast cancer treatment: Potential interactions with drug, gene, and pathophysiological conditions

Rossana Roncato, Jacopo Angelini, Arianna Pani, Erika Cecchin, Andrea Sartore-Bianchi, Salvatore Siena, Elena De Mattia, Francesco Scaglione, Giuseppe Toffoli

Research output: Contribution to journalArticlepeer-review

Abstract

Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals may experience increased and unexpected toxicity. This narrative review aims at identifying the factors potentially concurring at this variability for driving the most appropriate and tailored use of CDKis in the clinic. Specifically, concomitant medications, pharmacogenetic profile, and pathophysiological conditions could influence absorption, distribution, metabolism, and elimination pharmacokinetics. A personalized therapeutic approach taking into consideration all factors potentially contributing to an altered pharmacokinetic/pharmacodynamic profile could better drive safe and effective clinical use.

Original languageEnglish
Article number6350
Pages (from-to)1-36
Number of pages36
JournalInternational Journal of Molecular Sciences
Volume21
Issue number17
DOIs
Publication statusPublished - Sep 1 2020

Keywords

  • Breast cancer
  • Cyclin-dependent kinases inhibitors
  • Personalized medicine

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Fingerprint Dive into the research topics of 'Cdk4/6 inhibitors in breast cancer treatment: Potential interactions with drug, gene, and pathophysiological conditions'. Together they form a unique fingerprint.

Cite this